Practice Locations

map pin

About Fotios Asimakopoulos, MB BChir, PhD

Fotios (Fotis) Asimakopoulos, MB BChir, PhD, is a medical oncologist and hematologist who treats people with plasma cell dyscrasias, also known as plasma cell disorders. His patients may have blood-related diseases such as multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), amyloidosis, and Waldenstrom's macroglobulinemia (a type of lymphoma).

He offers a variety of highly advanced treatment options, including immunotherapy, cellular therapy, stem cell transplantation, and tumor cell vaccines. Dr. Asimakopoulos is part of the joint UC San Diego Health / Sharp HealthCare Blood and Marrow Transplantation (BMT) Program, one of the largest and most respected BMT units in California, where patients receive care from the same physician throughout all phases of blood cancer treatment. This includes initial consultation and diagnosis, treatment to help achieve remission, care throughout stem cell transplants, and follow-up survivorship care.

As an associate professor in residence of medicine, Dr. Asimakopoulos is involved in training medical students, residents and fellows in hematology and oncology at UC San Diego School of Medicine, where he is the Robert J. Shillman Scholar in Cancer Research. He is an active researcher and his research is funded by the American Cancer Society and the Leukemia and Lymphoma Society.

Prior to joining UC San Diego Health in 2019, Dr. Asimakopoulos was a physician at the University of Wisconsin's Carbone Cancer Center and tenured associate professor at the University of Wisconsin School of Medicine and Public Health in Madison. He also served as scientific director of the University of Wisconsin's Myeloma Study Group.

Dr. Asimakopoulos completed a fellowship in medical oncology and a research fellowship in clinical oncology at Memorial Sloan Kettering Cancer Center in New York. He completed residency training in internal medicine at Harvard Medical School Brigham and Women's Hospital. Dr. Asimakopoulos earned his medical (MB BChir) and doctoral degrees from University of Cambridge, United Kingdom. He also received training in hematology and cancer research as Golda Meir Fellow at the Hebrew University of Jerusalem, Israel.

He is a member of the American Society of Hematology, the International Myeloma Society, the American Association of Immunologists, the American Association for Cancer Research, and the Society for Leukocyte Biology.

Dr. Asimakopoulos speaks fluent Greek and conversational French and Italian.

UC San Diego Health Links
For more information, see Blood Cancers and Cancer Care.

Insurance Information
UC San Diego Health accepts most major health insurance plans, but you should verify that your plan covers this provider and all services and locations. The information in the link below does not apply to affiliate providers, who are not employed by UC San Diego Health.
Health Insurance Plans Accepted

Medical Degree

  • University of Cambridge, Cambridge, England

Fellowship

  • Memorial Sloan Kettering Cancer Center, New York, NY

Residency

  • Harvard Medical School, Brigham and Women's Hospital, Boston, MA

Gender

  • Male

Languages

  • Greek

Date Joined Staff

  • 2019-11-01

Conditions and Treatments

  • Plasma Cell Dyscrasias
  • Multiple Myeloma
  • Amyloidosis
  • Blood and Marrow Stem Cell Transplantation
  • Cell-Based Immunotherapy
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Waldenstrom's Macroglobulinemia
  • Tumor Cell Vaccines
Insurance Information
UC San Diego Health accepts most major health insurance plans, but you should verify that your plan covers this provider and all services and locations. The information in the link below does not apply to affiliate providers, who are not employed by UC San Diego Health.
Health Insurance Plans Accepted
  • Cancer

Videos

San Diego's only Comprehensive Cancer Center

As a NCI-designated Comprehensive Cancer Center, we hold the highest possible rating for a U.S. cancer center. This designation is reserved for centers with experts in every medical subspecialty, pushing boundaries to improve approaches for preventing, diagnosing and treating cancers. In simple terms, these federally recognized centers save lives. Studies repeatedly show that patients seen at NCI-designated Comprehensive Cancer Centers do better, on average.
More videos

News